{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:02:17Z","timestamp":1787166137349,"version":"build-2736575974"},"reference-count":159,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00520-025-10141-4","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T16:15:10Z","timestamp":1764692110000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Neutropenic events associated with new anticancer treatments, from pathophysiology to practice: a scoping review\u2014NEW Group (Neutropenic Events Working Group)"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6043-2580","authenticated-orcid":false,"given":"Gabriel","family":"Antherieu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Thibaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Sesques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Jacot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karima","family":"Menia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lodovico","family":"Balducci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Falandry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"key":"10141_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2020.598100","volume":"8","author":"CM Siamof","year":"2020","unstructured":"Siamof CM, Goel S, Cai W (2020) Moving beyond the pillars of cancer treatment: perspectives from nanotechnology. Front Chem 8:598100. https:\/\/doi.org\/10.3389\/fchem.2020.598100","journal-title":"Front Chem"},{"issue":"3","key":"10141_CR2","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrc2602","volume":"9","author":"M Malumbres","year":"2009","unstructured":"Malumbres M, Barbacid M (2009) Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 9(3):153\u2013166. https:\/\/doi.org\/10.1038\/nrc2602","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"10141_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030738","volume":"12","author":"RK Vaddepally","year":"2020","unstructured":"Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB (2020) Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers (Basel) 12(3):738. https:\/\/doi.org\/10.3390\/cancers12030738","journal-title":"Cancers (Basel)"},{"key":"10141_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-022-01324-x","author":"L Balducci","year":"2022","unstructured":"Balducci L, Falandry C, List A (2022) New advances in supportive care: chemoprotective agents as novel opportunities in geriatric oncology. Curr Oncol Rep. https:\/\/doi.org\/10.1007\/s11912-022-01324-x","journal-title":"Curr Oncol Rep"},{"issue":"3","key":"10141_CR5","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1080\/17512433.2021.1884067","volume":"14","author":"BL Rapoport","year":"2021","unstructured":"Rapoport BL, Cooksley T, Johnson DB, Anderson R, Shannon VR (2021) Treatment of infections in cancer patients: an update from the neutropenia, infection and myelosuppression study group of the Multinational Association for Supportive Care in Cancer (MASCC). Expert Rev Clin Pharmacol 14(3):295\u2013313. https:\/\/doi.org\/10.1080\/17512433.2021.1884067","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"28","key":"10141_CR6","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith TJ, Bohlke K, Lyman GH et al (2015) Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 33(28):3199\u20133212. https:\/\/doi.org\/10.1200\/JCO.2015.62.3488","journal-title":"J Clin Oncol"},{"key":"10141_CR7","doi-asserted-by":"crossref","unstructured":"Klastersky J. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2016;27.","DOI":"10.1093\/annonc\/mdw325"},{"key":"10141_CR8","doi-asserted-by":"crossref","unstructured":"Aapro MS. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. Published online 2010.","DOI":"10.1016\/j.ejca.2010.10.013"},{"issue":"4","key":"10141_CR9","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.coi.2010.05.003","volume":"22","author":"AC Shaw","year":"2010","unstructured":"Shaw AC, Joshi S, Greenwood H, Panda A, Lord JM (2010) Aging of the innate immune system. Curr Opin Immunol 22(4):507\u2013513. https:\/\/doi.org\/10.1016\/j.coi.2010.05.003","journal-title":"Curr Opin Immunol"},{"key":"10141_CR10","doi-asserted-by":"publisher","unstructured":"Balducci L, Falandry C, Silvio Monfardini null. Senotherapy, cancer, and aging. J Geriatr Oncol. 2024;15(4):101671. https:\/\/doi.org\/10.1016\/j.jgo.2023.101671","DOI":"10.1016\/j.jgo.2023.101671"},{"issue":"7","key":"10141_CR11","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1111\/jgs.18350","volume":"71","author":"C Falandry","year":"2023","unstructured":"Falandry C, List A, Balducci L (2023) Cell cycle arrest: a breakthrough in the supportive care of older cancer patients. J Am Geriatr Soc 71(7):2297\u20132307. https:\/\/doi.org\/10.1111\/jgs.18350","journal-title":"J Am Geriatr Soc"},{"key":"10141_CR12","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.semcancer.2022.12.006","volume":"88","author":"MJ Mughal","year":"2023","unstructured":"Mughal MJ, Bhadresha K, Kwok HF (2023) CDK inhibitors from past to present: a new wave of cancer therapy. Semin Cancer Biol 88:106\u2013122. https:\/\/doi.org\/10.1016\/j.semcancer.2022.12.006","journal-title":"Semin Cancer Biol"},{"issue":"7","key":"10141_CR13","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nrclinonc.2016.26","volume":"13","author":"B O\u2019Leary","year":"2016","unstructured":"O\u2019Leary B, Finn RS, Turner NC (2016) Treating cancer with selective CDK4\/6 inhibitors. Nat Rev Clin Oncol 13(7):417\u2013430. https:\/\/doi.org\/10.1038\/nrclinonc.2016.26","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10141_CR14","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1159\/000499534","volume":"14","author":"J Ettl","year":"2019","unstructured":"Ettl J (2019) Management of adverse events due to cyclin-dependent kinase 4\/6 inhibitors. Breast Care 14(2):86\u201392. https:\/\/doi.org\/10.1159\/000499534","journal-title":"Breast Care"},{"issue":"8","key":"10141_CR15","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1158\/1078-0432.CCR-15-1421","volume":"22","author":"W Hu","year":"2016","unstructured":"Hu W, Sung T, Jessen BA et al (2016) Mechanistic investigation of bone marrow suppression associated with palbociclib and its differentiation from cytotoxic chemotherapies. Clin Cancer Res 22(8):2000\u20132008. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1421","journal-title":"Clin Cancer Res"},{"issue":"387","key":"10141_CR16","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aal3986","volume":"9","author":"S He","year":"2017","unstructured":"He S, Roberts PJ, Sorrentino JA et al (2017) Transient CDK4\/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion. Sci Transl Med 9(387):eaal3986. https:\/\/doi.org\/10.1126\/scitranslmed.aal3986","journal-title":"Sci Transl Med"},{"issue":"10","key":"10141_CR17","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1093\/annonc\/mdz278","volume":"30","author":"JM Weiss","year":"2019","unstructured":"Weiss JM, Csoszi T, Maglakelidze M et al (2019) Myelopreservation with the CDK4\/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib\/randomized phase II trial. Ann Oncol 30(10):1613\u20131621. https:\/\/doi.org\/10.1093\/annonc\/mdz278","journal-title":"Ann Oncol"},{"issue":"1","key":"10141_CR18","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1007\/s12325-020-01538-0","volume":"38","author":"LL Hart","year":"2021","unstructured":"Hart LL, Ferrarotto R, Andric ZG et al (2021) Myelopreservation with trilaciclib in patients receiving topotecan for small cell lung cancer: results from a randomized, double-blind, placebo-controlled phase II study. Adv Ther 38(1):350\u2013365. https:\/\/doi.org\/10.1007\/s12325-020-01538-0","journal-title":"Adv Ther"},{"issue":"7","key":"10141_CR19","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1002\/ijc.33705","volume":"149","author":"M D\u00f3mine G\u00f3mez","year":"2021","unstructured":"D\u00f3mine G\u00f3mez M, Cs\u0151szi T, Jaal J et al (2021) Exploratory composite endpoint demonstrates benefit of trilaciclib across multiple clinically meaningful components of myeloprotection in patients with small cell lung cancer. Int J Cancer 149(7):1463\u20131472. https:\/\/doi.org\/10.1002\/ijc.33705","journal-title":"Int J Cancer"},{"issue":"11","key":"10141_CR20","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1016\/S1470-2045(19)30616-3","volume":"20","author":"AR Tan","year":"2019","unstructured":"Tan AR, Wright GS, Thummala AR et al (2019) Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial. Lancet Oncol 20(11):1587\u20131601. https:\/\/doi.org\/10.1016\/S1470-2045(19)30616-3","journal-title":"Lancet Oncol"},{"key":"10141_CR21","unstructured":"vasquez lea, coussirou julie, Arvers P, et al. palbociclib-associated-with-endocrine-therapy-in-patients-with-metastatic-breast-cancer-predictive-factors-of-severe-ear. J Cancer Sci Ther. 2019;11:290\u2013294."},{"issue":"1","key":"10141_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-99504-5","volume":"11","author":"Y Kanbayashi","year":"2021","unstructured":"Kanbayashi Y, Sakaguchi K, Ishikawa T, Takayama K, Taguchi T (2021) Predictors for development of palbociclib-induced neutropenia in breast cancer patients as determined by ordered logistic regression analysis. Sci Rep 11(1):20055. https:\/\/doi.org\/10.1038\/s41598-021-99504-5","journal-title":"Sci Rep"},{"issue":"4","key":"10141_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14040841","volume":"14","author":"F Leenhardt","year":"2022","unstructured":"Leenhardt F, Fiteni F, Gauthier L et al (2022) Pharmacokinetic variability drives palbociclib-induced neutropenia in metastatic breast cancer patients: drug-drug interactions are the usual suspects. Pharmaceutics 14(4):841. https:\/\/doi.org\/10.3390\/pharmaceutics14040841","journal-title":"Pharmaceutics"},{"key":"10141_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115479","volume":"167","author":"E Peruzzi","year":"2023","unstructured":"Peruzzi E, Gerratana L, Montico M et al (2023) Association of ADME gene polymorphisms on toxicity to CDK4\/6 inhibitors in patients with HR+ HER2- metastatic breast cancer. Biomed Pharmacother 167:115479. https:\/\/doi.org\/10.1016\/j.biopha.2023.115479","journal-title":"Biomed Pharmacother"},{"issue":"7","key":"10141_CR25","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nrm1963","volume":"7","author":"V Schreiber","year":"2006","unstructured":"Schreiber V, Dantzer F, Ame JC, de Murcia G (2006) Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 7(7):517\u2013528. https:\/\/doi.org\/10.1038\/nrm1963","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6367","key":"10141_CR26","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/356356a0","volume":"356","author":"MS Satoh","year":"1992","unstructured":"Satoh MS, Lindahl T (1992) Role of poly(ADP-ribose) formation in DNA repair. Nature 356(6367):356\u2013358. https:\/\/doi.org\/10.1038\/356356a0","journal-title":"Nature"},{"issue":"37 REV. ISS. 3","key":"10141_CR27","doi-asserted-by":"publisher","first-page":"5792","DOI":"10.1038\/sj.onc.1206679","volume":"22","author":"K Valerie","year":"2003","unstructured":"Valerie K, Povirk LF (2003) Regulation and mechanisms of mammalian double-strand break repair. Oncogene 22(37 REV. ISS. 3):5792\u20135812. https:\/\/doi.org\/10.1038\/sj.onc.1206679","journal-title":"Oncogene"},{"issue":"6330","key":"10141_CR28","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1126\/science.aam7344","volume":"355","author":"CJ Lord","year":"2017","unstructured":"Lord CJ, Ashworth A (2017) PARP inhibitors: synthetic lethality in the clinic. Science 355(6330):1152\u20131158. https:\/\/doi.org\/10.1126\/science.aam7344","journal-title":"Science"},{"issue":"7035","key":"10141_CR29","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer H, McCabe N, Lord CJ et al (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434(7035):917\u2013921. https:\/\/doi.org\/10.1038\/nature03445","journal-title":"Nature"},{"issue":"3","key":"10141_CR30","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","volume":"33","author":"B Kaufman","year":"2015","unstructured":"Kaufman B, Shapira-Frommer R, Schmutzler RK et al (2015) Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation. J Clin Oncol 33(3):244\u2013250. https:\/\/doi.org\/10.1200\/JCO.2014.56.2728","journal-title":"J Clin Oncol"},{"issue":"19","key":"10141_CR31","doi-asserted-by":"publisher","first-page":"4257","DOI":"10.1158\/1078-0432.CCR-15-0887","volume":"21","author":"G Kim","year":"2015","unstructured":"Kim G, Ison G, McKee AE et al (2015) FDA approval summary: olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy. Clin Cancer Res 21(19):4257\u20134261. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0887","journal-title":"Clin Cancer Res"},{"issue":"25","key":"10141_CR32","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/nejmoa1910962","volume":"381","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2019","unstructured":"Gonz\u00e1lez-Mart\u00edn A, Pothuri B, Vergote I et al (2019) Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 381(25):2391\u20132402. https:\/\/doi.org\/10.1056\/nejmoa1910962","journal-title":"N Engl J Med"},{"issue":"25","key":"10141_CR33","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/nejmoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard I, Pautier P, Pignata S et al (2019) Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med 381(25):2416\u20132428. https:\/\/doi.org\/10.1056\/nejmoa1911361","journal-title":"N Engl J Med"},{"issue":"22","key":"10141_CR34","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/nejmoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza MR, Monk BJ, Herrstedt J et al (2016) Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 375(22):2154\u20132164. https:\/\/doi.org\/10.1056\/nejmoa1611310","journal-title":"N Engl J Med"},{"issue":"10106","key":"10141_CR35","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","volume":"390","author":"RL Coleman","year":"2017","unstructured":"Coleman RL, Oza AM, Lorusso D et al (2017) Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390(10106):1949\u20131961. https:\/\/doi.org\/10.1016\/S0140-6736(17)32440-6","journal-title":"Lancet"},{"issue":"1","key":"10141_CR36","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/S1470-2045(18)30786-1","volume":"20","author":"CJ LaFargue","year":"2019","unstructured":"LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL (2019) Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol 20(1):e15\u2013e28. https:\/\/doi.org\/10.1016\/S1470-2045(18)30786-1","journal-title":"Lancet Oncol"},{"issue":"7145","key":"10141_CR37","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/nature05862","volume":"447","author":"DJ Rossi","year":"2007","unstructured":"Rossi DJ, Bryder D, Seita J, Nussenzweig A, Hoeijmakers J, Weissman IL (2007) Deficiencies in DNA damage repair limit the function of haematopoietic stem cells with age. Nature 447(7145):725\u2013729. https:\/\/doi.org\/10.1038\/nature05862","journal-title":"Nature"},{"issue":"1","key":"10141_CR38","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1182\/blood-2012-12-472845","volume":"122","author":"J Farre\u015b","year":"2013","unstructured":"Farre\u015b J, Mart\u00edn-Caballero J, Mart\u00ednez C et al (2013) Parp-2 is required to maintain hematopoiesis following sublethal \u03b3-irradiation in mice. Blood 122(1):44\u201354. https:\/\/doi.org\/10.1182\/blood-2012-12-472845","journal-title":"Blood"},{"issue":"7","key":"10141_CR39","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/cdd.2014.202","volume":"22","author":"J Farr\u00e9s","year":"2015","unstructured":"Farr\u00e9s J, Llacuna L, Martin-Caballero J et al (2015) PARP-2 sustains erythropoiesis in mice by limiting replicative stress in erythroid progenitors. Cell Death Differ 22(7):1144\u20131157. https:\/\/doi.org\/10.1038\/cdd.2014.202","journal-title":"Cell Death Differ"},{"key":"10141_CR40","unstructured":"Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma | Blood Cancer Journal. Accessed December 28, 2023. https:\/\/www.nature.com\/articles\/s41408-022-00741-2"},{"issue":"4","key":"10141_CR41","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S1470-2045(18)30111-6","volume":"19","author":"S Loibl","year":"2018","unstructured":"Loibl S, O\u2019Shaughnessy J, Untch M et al (2018) Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol 19(4):497\u2013509. https:\/\/doi.org\/10.1016\/S1470-2045(18)30111-6","journal-title":"Lancet Oncol"},{"issue":"25","key":"10141_CR42","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","volume":"384","author":"ANJ Tutt","year":"2021","unstructured":"Tutt ANJ, Garber JE, Kaufman B et al (2021) Adjuvant olaparib for patients with BRCA1 - or BRCA2 -mutated breast cancer. N Engl J Med 384(25):2394\u20132405. https:\/\/doi.org\/10.1056\/NEJMoa2105215","journal-title":"N Engl J Med"},{"issue":"22","key":"10141_CR43","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1200\/JCO.21.01511","volume":"40","author":"N Li","year":"2022","unstructured":"Li N, Zhang Y, Wang J et al (2022) Fuzuloparib maintenance therapy in patients with platinum-sensitive, recurrent ovarian carcinoma (FZOCUS-2): a multicenter, randomized, double-blind, placebo-controlled, phase III trial. J Clin Oncol 40(22):2436\u20132446. https:\/\/doi.org\/10.1200\/JCO.21.01511","journal-title":"J Clin Oncol"},{"issue":"4","key":"10141_CR44","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","volume":"381","author":"T Golan","year":"2019","unstructured":"Golan T, Hammel P, Reni M et al (2019) Maintenance olaparib for germline BRCA -mutated metastatic pancreatic cancer. N Engl J Med 381(4):317\u2013327. https:\/\/doi.org\/10.1056\/NEJMoa1903387","journal-title":"N Engl J Med"},{"issue":"26","key":"10141_CR45","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore K, Colombo N, Scambia G et al (2018) Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 379(26):2495\u20132505. https:\/\/doi.org\/10.1056\/NEJMoa1810858","journal-title":"N Engl J Med"},{"issue":"4","key":"10141_CR46","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.annonc.2020.12.018","volume":"32","author":"XH Wu","year":"2021","unstructured":"Wu XH, Zhu JQ, Yin RT et al (2021) Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial\u2606. Ann Oncol 32(4):512\u2013521. https:\/\/doi.org\/10.1016\/j.annonc.2020.12.018","journal-title":"Ann Oncol"},{"issue":"6","key":"10141_CR47","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M, Im SA, Senkus E et al (2017) Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 377(6):523\u2013533. https:\/\/doi.org\/10.1056\/NEJMoa1706450","journal-title":"N Engl J Med"},{"issue":"22","key":"10141_CR48","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J de Bono","year":"2020","unstructured":"de Bono J, Mateo J, Fizazi K et al (2020) Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med 382(22):2091\u20132102. https:\/\/doi.org\/10.1056\/NEJMoa1911440","journal-title":"N Engl J Med"},{"issue":"9","key":"10141_CR49","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","volume":"18","author":"E Pujade-Lauraine","year":"2017","unstructured":"Pujade-Lauraine E, Ledermann JA, Selle F et al (2017) Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 18(9):1274\u20131284. https:\/\/doi.org\/10.1016\/S1470-2045(17)30469-2","journal-title":"Lancet Oncol"},{"key":"10141_CR50","doi-asserted-by":"publisher","unstructured":"Penson RT, Villalobos Valencia R, David Cibula ;, et al. Olaparib versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer and a germline BRCA1\/2 mutation (SOLO3): a randomized phase III trial. J Clin Oncol. 2020;38:1164\u20131174. https:\/\/doi.org\/10.1200\/JCO.19","DOI":"10.1200\/JCO.19"},{"issue":"19","key":"10141_CR51","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1200\/JCO.21.02011","volume":"40","author":"JF Liu","year":"2022","unstructured":"Liu JF, Brady MF, Matulonis UA et al (2022) Olaparib with or without cediranib versus platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer (NRG-GY004): a randomized, open-label, phase III trial. J Clin Oncol 40(19):2138\u20132147. https:\/\/doi.org\/10.1200\/JCO.21.02011","journal-title":"J Clin Oncol"},{"issue":"4","key":"10141_CR52","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S1470-2045(22)00122-X","volume":"23","author":"R Kristeleit","year":"2022","unstructured":"Kristeleit R, Lisyanskaya A, Fedenko A et al (2022) Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial. Lancet Oncol 23(4):465\u2013478. https:\/\/doi.org\/10.1016\/S1470-2045(22)00122-X","journal-title":"Lancet Oncol"},{"issue":"8","key":"10141_CR53","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa1802905","volume":"379","author":"JK Litton","year":"2018","unstructured":"Litton JK, Rugo HS, Ettl J et al (2018) Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med 379(8):753\u2013763. https:\/\/doi.org\/10.1056\/NEJMoa1802905","journal-title":"N Engl J Med"},{"issue":"32","key":"10141_CR54","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.1200\/JCO.20.03318","volume":"39","author":"SS Ramalingam","year":"2021","unstructured":"Ramalingam SS, Novello S, Guclu SZ et al (2021) Veliparib in combination with platinum-based chemotherapy for first-line treatment of advanced squamous cell lung cancer: a randomized, multicenter phase III study. J Clin Oncol 39(32):3633\u20133644. https:\/\/doi.org\/10.1200\/JCO.20.03318","journal-title":"J Clin Oncol"},{"issue":"10","key":"10141_CR55","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/S1470-2045(20)30447-2","volume":"21","author":"V Di\u00e9ras","year":"2020","unstructured":"Di\u00e9ras V, Han HS, Kaufman B et al (2020) Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21(10):1269\u20131282. https:\/\/doi.org\/10.1016\/S1470-2045(20)30447-2","journal-title":"Lancet Oncol"},{"issue":"25","key":"10141_CR56","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","volume":"381","author":"RL Coleman","year":"2019","unstructured":"Coleman RL, Fleming GF, Brady MF et al (2019) Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N Engl J Med 381(25):2403\u20132415. https:\/\/doi.org\/10.1056\/NEJMoa1909707","journal-title":"N Engl J Med"},{"key":"10141_CR57","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009016","author":"MH Kroll","year":"2022","unstructured":"Kroll MH, Rojas-Hernandez C, Yee C (2022) Hematologic complications of immune checkpoint inhibitors. Blood. https:\/\/doi.org\/10.1182\/blood.2020009016","journal-title":"Blood"},{"issue":"6","key":"10141_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061440","volume":"13","author":"N Sobhani","year":"2021","unstructured":"Sobhani N, Tardiel-Cyril DR, Davtyan A, Generali D, Roudi R, Li Y (2021) CTLA-4 in regulatory T cells for cancer immunotherapy. Cancers (Basel) 13(6):1440. https:\/\/doi.org\/10.3390\/cancers13061440","journal-title":"Cancers (Basel)"},{"issue":"6029","key":"10141_CR59","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1126\/science.1202947","volume":"332","author":"OS Qureshi","year":"2011","unstructured":"Qureshi OS, Zheng Y, Nakamura K et al (2011) Trans-endocytosis of CD80 and CD86: a molecular basis for the cell extrinsic function of CTLA-4. Science 332(6029):600\u2013603. https:\/\/doi.org\/10.1126\/science.1202947","journal-title":"Science"},{"issue":"9","key":"10141_CR60","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1158\/2159-8290.CD-15-0563","volume":"5","author":"A Ribas","year":"2015","unstructured":"Ribas A (2015) Adaptive immune resistance: how cancer protects from immune attack. Cancer Discov 5(9):915\u2013919. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-0563","journal-title":"Cancer Discov"},{"issue":"2","key":"10141_CR61","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/ni.2496","volume":"14","author":"PT Sage","year":"2013","unstructured":"Sage PT, Francisco LM, Carman CV, Sharpe AH (2013) PD-1 controls lymph node and blood T follicular regulatory cells. Nat Immunol 14(2):152\u2013161. https:\/\/doi.org\/10.1038\/ni.2496","journal-title":"Nat Immunol"},{"issue":"2","key":"10141_CR62","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000873","volume":"8","author":"JE Park","year":"2020","unstructured":"Park JE, Kim SE, Keam B et al (2020) Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines. J Immunother Cancer 8(2):e000873. https:\/\/doi.org\/10.1136\/jitc-2020-000873","journal-title":"J Immunother Cancer"},{"key":"10141_CR63","unstructured":"Kroll MH, Rojas-Hernandez C, Yee C. Hematologic complications of immune checkpoint inhibitors."},{"issue":"5","key":"10141_CR64","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1634\/theoncologist.2018-0574","volume":"24","author":"EJ Davis","year":"2019","unstructured":"Davis EJ, Salem J, Young A et al (2019) Hematologic complications of immune checkpoint inhibitors. Oncologist 24(5):584\u2013588. https:\/\/doi.org\/10.1634\/theoncologist.2018-0574","journal-title":"Oncologist"},{"issue":"5","key":"10141_CR65","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.trsl.2015.06.005","volume":"166","author":"SK Quirk","year":"2015","unstructured":"Quirk SK, Shure AK, Agrawal DK (2015) Immune-mediated adverse effects of anti-CTLA-4 antibody therapy in metastatic melanoma. Transl Res J Lab Clin Med 166(5):412\u2013424. https:\/\/doi.org\/10.1016\/j.trsl.2015.06.005","journal-title":"Transl Res J Lab Clin Med"},{"key":"10141_CR66","doi-asserted-by":"publisher","unstructured":"Omar NE, El-Fass KA, Abushouk AI, et al. Diagnosis and management of hematological adverse events induced by immune checkpoint inhibitors: a systematic review. Front Immunol. 2020;11. Accessed December 11, 2022. https:\/\/www.frontiersin.org\/articles\/https:\/\/doi.org\/10.3389\/fimmu.2020.01354","DOI":"10.3389\/fimmu.2020.01354"},{"issue":"29","key":"10141_CR67","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000004283","volume":"95","author":"K Inadomi","year":"2016","unstructured":"Inadomi K, Kumagai H, Arita S et al (2016) Bi-cytopenia possibly induced by anti-PD-1 antibody for primary malignant melanoma of the esophagus. Medicine (Baltimore) 95(29):e4283. https:\/\/doi.org\/10.1097\/MD.0000000000004283","journal-title":"Medicine (Baltimore)"},{"key":"10141_CR68","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ejca.2018.07.129","volume":"103","author":"F Petrelli","year":"2018","unstructured":"Petrelli F, Ardito R, Borgonovo K et al (2018) Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis. Eur J Cancer 103:7\u201316. https:\/\/doi.org\/10.1016\/j.ejca.2018.07.129","journal-title":"Eur J Cancer"},{"issue":"1","key":"10141_CR69","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0648-3","volume":"7","author":"AR Naqash","year":"2019","unstructured":"Naqash AR, Appah E, Yang LV et al (2019) Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition. J Immunother Cancer 7(1):169. https:\/\/doi.org\/10.1186\/s40425-019-0648-3","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10141_CR70","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1016\/S2352-3026(18)30175-3","volume":"6","author":"N Delanoy","year":"2019","unstructured":"Delanoy N, Michot JM, Comont T et al (2019) Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. Lancet Haematol 6(1):e48\u2013e57. https:\/\/doi.org\/10.1016\/S2352-3026(18)30175-3","journal-title":"Lancet Haematol"},{"issue":"12","key":"10141_CR71","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen J, Obeid M, Spain L et al (2022) Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up\u2606. Ann Oncol 33(12):1217\u20131238. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.001","journal-title":"Ann Oncol"},{"issue":"2","key":"10141_CR72","doi-asserted-by":"publisher","first-page":"66","DOI":"10.14740\/jh1090","volume":"12","author":"T Ohashi","year":"2023","unstructured":"Ohashi T, Takase-Minegishi K, Maeda A et al (2023) Incidence and risk of hematological adverse events associated with immune checkpoint inhibitors: a systematic literature review and meta-analysis. J Hematol 12(2):66\u201374. https:\/\/doi.org\/10.14740\/jh1090","journal-title":"J Hematol"},{"key":"10141_CR73","doi-asserted-by":"publisher","first-page":"1163971","DOI":"10.3389\/fphar.2023.1163971","volume":"14","author":"J Hou","year":"2023","unstructured":"Hou J, Xie R, Zhang Z, Liu Q, Xiang Q, Cui Y (2023) Hematologic side effects of immune checkpoint inhibitor with or without chemotherapy in patients with advanced and metastatic gastrointestinal cancer: a systematic review and network meta-analysis of phase 3 trials. Front Pharmacol 14:1163971. https:\/\/doi.org\/10.3389\/fphar.2023.1163971","journal-title":"Front Pharmacol"},{"issue":"17","key":"10141_CR74","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol Off J Am Soc Clin Oncol 36(17):1714\u20131768. https:\/\/doi.org\/10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"36","key":"10141_CR75","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD et al (2021) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 39(36):4073\u20134126. https:\/\/doi.org\/10.1200\/JCO.21.01440","journal-title":"J Clin Oncol"},{"key":"10141_CR76","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.5376","author":"R Marcus","year":"2008","unstructured":"Marcus R, Imrie K, Solal-Celigny P et al (2008) Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2007.13.5376","journal-title":"J Clin Oncol"},{"issue":"4","key":"10141_CR77","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Bri\u00e8re J et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346(4):235\u2013242. https:\/\/doi.org\/10.1056\/NEJMoa011795","journal-title":"N Engl J Med"},{"issue":"5","key":"10141_CR78","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1200\/JCO.2011.40.6272","volume":"31","author":"E Zucca","year":"2013","unstructured":"Zucca E, Conconi A, Laszlo D et al (2013) Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 randomized study. J Clin Oncol 31(5):565\u2013572. https:\/\/doi.org\/10.1200\/JCO.2011.40.6272","journal-title":"J Clin Oncol"},{"issue":"9","key":"10141_CR79","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.autrev.2011.11.007","volume":"11","author":"JA G\u00f3mez-Puerta","year":"2012","unstructured":"G\u00f3mez-Puerta JA, Quintana LF, Stone JH, Ramos-Casals M, Bosch X (2012) B-cell depleting agents for ANCA vasculitides: a new therapeutic approach. Autoimmun Rev 11(9):646\u2013652. https:\/\/doi.org\/10.1016\/j.autrev.2011.11.007","journal-title":"Autoimmun Rev"},{"issue":"9","key":"10141_CR80","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/nrneph.2012.141","volume":"8","author":"JW Gregersen","year":"2012","unstructured":"Gregersen JW, Jayne DRW (2012) B-cell depletion in the treatment of lupus nephritis. Nat Rev Nephrol 8(9):505\u2013514. https:\/\/doi.org\/10.1038\/nrneph.2012.141","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"10141_CR81","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.jbspin.2014.06.011","volume":"81","author":"M Sebastiani","year":"2014","unstructured":"Sebastiani M, Anelli MG, Atzeni F et al (2014) Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: results from the GISEA register. Joint Bone Spine 81(6):508\u2013512. https:\/\/doi.org\/10.1016\/j.jbspin.2014.06.011","journal-title":"Joint Bone Spine"},{"issue":"22","key":"10141_CR82","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","volume":"115","author":"E M\u00f6ssner","year":"2010","unstructured":"M\u00f6ssner E, Br\u00fcnker P, Moser S et al (2010) Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell\u2013mediated B-cell cytotoxicity. Blood 115(22):4393\u20134402. https:\/\/doi.org\/10.1182\/blood-2009-06-225979","journal-title":"Blood"},{"issue":"10","key":"10141_CR83","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1158\/1535-7163.MCT-12-1182","volume":"12","author":"S Herter","year":"2013","unstructured":"Herter S, Herting F, Mundigl O et al (2013) Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther 12(10):2031\u20132042. https:\/\/doi.org\/10.1158\/1535-7163.MCT-12-1182","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"10141_CR84","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1428158","volume":"7","author":"S Elias","year":"2018","unstructured":"Elias S, Kahlon S, Kotzur R, Kaynan N, Mandelboim O (2018) Obinutuzumab activates Fc\u03b3RI more potently than other anti-CD20 antibodies in chronic lymphocytic leukemia (CLL). Oncoimmunology 7(6):e1428158. https:\/\/doi.org\/10.1080\/2162402X.2018.1428158","journal-title":"Oncoimmunology"},{"issue":"6","key":"10141_CR85","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1080\/10428190500473113","volume":"47","author":"C Cattaneo","year":"2006","unstructured":"Cattaneo C, Spedini P, Casari S et al (2006) Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments. Leuk Lymphoma 47(6):1013\u20131017. https:\/\/doi.org\/10.1080\/10428190500473113","journal-title":"Leuk Lymphoma"},{"issue":"17","key":"10141_CR86","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1200\/JCO.2000.18.17.3135","volume":"18","author":"TA Davis","year":"2000","unstructured":"Davis TA, Grillo-L\u00f3pez AJ, White CA et al (2000) Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin\u2019s lymphoma: safety and efficacy of re-treatment. J Clin Oncol Off J Am Soc Clin Oncol 18(17):3135\u20133143. https:\/\/doi.org\/10.1200\/JCO.2000.18.17.3135","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10141_CR87","doi-asserted-by":"publisher","unstructured":"Voog E, Morschhauser F, Solal-C\u00e9ligny P. Neutropenia in patients treated with rituximab. N Engl J Med. 2003;348(26):2691\u20132694; discussion 2691\u20132694. https:\/\/doi.org\/10.1056\/NEJM200306263482620","DOI":"10.1056\/NEJM200306263482620"},{"issue":"10","key":"10141_CR88","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1182\/blood.V95.10.3219","volume":"95","author":"JH Liu","year":"2000","unstructured":"Liu JH, Wei S, Lamy T et al (2000) Chronic neutropenia mediated by Fas ligand. Blood 95(10):3219\u20133222. https:\/\/doi.org\/10.1182\/blood.V95.10.3219","journal-title":"Blood"},{"issue":"7","key":"10141_CR89","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1038\/sj.leu.2405077","volume":"22","author":"K Stamatopoulos","year":"2008","unstructured":"Stamatopoulos K, Papadaki T, Pontikoglou C et al (2008) Lymphocyte subpopulation imbalances, bone marrow hematopoiesis and histopathology in rituximab-treated lymphoma patients with late-onset neutropenia. Leukemia 22(7):1446\u20131449. https:\/\/doi.org\/10.1038\/sj.leu.2405077","journal-title":"Leukemia"},{"issue":"4","key":"10141_CR90","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/S1074-7613(00)80046-1","volume":"10","author":"Q Ma","year":"1999","unstructured":"Ma Q, Jones D, Springer TA (1999) The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment. Immunity 10(4):463\u2013471. https:\/\/doi.org\/10.1016\/S1074-7613(00)80046-1","journal-title":"Immunity"},{"issue":"2","key":"10141_CR91","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.3324\/haematol.11031","volume":"92","author":"B Terrier","year":"2007","unstructured":"Terrier B, Ittah M, Tourneur L et al (2007) Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery. Haematologica 92(2):e20\u2013e23. https:\/\/doi.org\/10.3324\/haematol.11031","journal-title":"Haematologica"},{"issue":"5","key":"10141_CR92","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1097\/MD.0b013e3181f2caef","volume":"89","author":"O Wolach","year":"2010","unstructured":"Wolach O, Bairey O, Lahav M (2010) Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature. Medicine (Baltimore) 89(5):308\u2013318. https:\/\/doi.org\/10.1097\/MD.0b013e3181f2caef","journal-title":"Medicine (Baltimore)"},{"key":"10141_CR93","doi-asserted-by":"publisher","unstructured":"Zhang X, Rao M, Xu G. An update on the incidence, risk factors and mechanisms of rituximab-associated neutropenia. Arch Med Sci. Published online September 15, 2022. https:\/\/doi.org\/10.5114\/aoms\/152174","DOI":"10.5114\/aoms\/152174"},{"issue":"1","key":"10141_CR94","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2014-000034","volume":"1","author":"JH Salmon","year":"2015","unstructured":"Salmon JH, Cacoub P, Combe B et al (2015) Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the autoimmunity and rituximab registry. RMD Open 1(1):e000034. https:\/\/doi.org\/10.1136\/rmdopen-2014-000034","journal-title":"RMD Open"},{"issue":"2","key":"10141_CR95","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/art.41501","volume":"73","author":"R Zonozi","year":"2021","unstructured":"Zonozi R, Wallace ZS, Laliberte K et al (2021) Incidence, clinical features, and outcomes of late-onset neutropenia from rituximab for autoimmune disease. Arthritis Rheumatol 73(2):347\u2013354. https:\/\/doi.org\/10.1002\/art.41501","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10141_CR96","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/hon.2828","volume":"39","author":"I Amitai","year":"2021","unstructured":"Amitai I, Gafter-Gvili A, Shargian-Alon L, Raanani P, Gurion R (2021) Obinutuzumab-related adverse events: a systematic review and meta-analysis. Hematol Oncol 39(2):215\u2013221. https:\/\/doi.org\/10.1002\/hon.2828","journal-title":"Hematol Oncol"},{"issue":"12","key":"10141_CR97","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1080\/10428194.2021.1948037","volume":"62","author":"S Shimony","year":"2021","unstructured":"Shimony S, Bar-Sever E, Berger T et al (2021) Late onset neutropenia after rituximab and obinutuzumab treatment \u2013 characteristics of a class-effect toxicity. Leuk Lymphoma 62(12):2921\u20132927. https:\/\/doi.org\/10.1080\/10428194.2021.1948037","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10141_CR98","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1007\/s00228-013-1518-4","volume":"69","author":"I Dan\u00e9s","year":"2013","unstructured":"Dan\u00e9s I, Agust\u00ed A, Vallano A et al (2013) Available evidence and outcome of off-label use of rituximab in clinical practice. Eur J Clin Pharmacol 69(9):1689\u20131699. https:\/\/doi.org\/10.1007\/s00228-013-1518-4","journal-title":"Eur J Clin Pharmacol"},{"key":"10141_CR99","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.798251","volume":"12","author":"R Diez-Feij\u00f3o","year":"2022","unstructured":"Diez-Feij\u00f3o R, Rodr\u00edguez-Sevilla JJ, Fern\u00e1ndez-Rodr\u00edguez C et al (2022) Case report: high doses of intravenous immunoglobulins as a successful treatment for late onset immune agranulocytosis after rituximab plus bendamustine. Front Immunol 12:798251. https:\/\/doi.org\/10.3389\/fimmu.2021.798251","journal-title":"Front Immunol"},{"issue":"10","key":"10141_CR100","doi-asserted-by":"publisher","first-page":"4225","DOI":"10.1182\/blood-2003-02-0450","volume":"101","author":"AL Rose","year":"2003","unstructured":"Rose AL, Forsythe AM, Maloney DG (2003) Agranulocytosis unresponsive to growth factors following rituximab in vivo purging. Blood 101(10):4225\u20134226. https:\/\/doi.org\/10.1182\/blood-2003-02-0450","journal-title":"Blood"},{"issue":"1","key":"10141_CR101","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA et al (2019) Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol 20(1):31\u201342. https:\/\/doi.org\/10.1016\/S1470-2045(18)30864-7","journal-title":"Lancet Oncol"},{"issue":"26","key":"10141_CR102","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL et al (2017) Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 377(26):2531\u20132544. https:\/\/doi.org\/10.1056\/NEJMoa1707447","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"10141_CR103","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1182\/blood-2018-99-117199","volume":"132","author":"CA Jacobson","year":"2018","unstructured":"Jacobson CA, Hunter B, Armand P et al (2018) Axicabtagene ciloleucel in the real world: outcomes and predictors of response, resistance and toxicity. Blood 132(Supplement 1):92\u201392. https:\/\/doi.org\/10.1182\/blood-2018-99-117199","journal-title":"Blood"},{"issue":"27","key":"10141_CR104","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.19.02104","volume":"38","author":"LJ Nastoupil","year":"2020","unstructured":"Nastoupil LJ, Jain MD, Feng L et al (2020) Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium. J Clin Oncol Off J Am Soc Clin Oncol 38(27):3119\u20133128. https:\/\/doi.org\/10.1200\/JCO.19.02104","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"5","key":"10141_CR105","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J et al (2018) Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 378(5):439\u2013448. https:\/\/doi.org\/10.1056\/NEJMoa1709866","journal-title":"N Engl J Med"},{"issue":"1","key":"10141_CR106","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS et al (2019) Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 380(1):45\u201356. https:\/\/doi.org\/10.1056\/NEJMoa1804980","journal-title":"N Engl J Med"},{"issue":"10297","key":"10141_CR107","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ et al (2021) Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet 398(10297):314\u2013324. https:\/\/doi.org\/10.1016\/S0140-6736(21)00933-8","journal-title":"Lancet"},{"issue":"8","key":"10141_CR108","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD, Shah N et al (2021) Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med 384(8):705\u2013716. https:\/\/doi.org\/10.1056\/NEJMoa2024850","journal-title":"N Engl J Med"},{"issue":"10254","key":"10141_CR109","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI et al (2020) Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396(10254):839\u2013852. https:\/\/doi.org\/10.1016\/S0140-6736(20)31366-0","journal-title":"Lancet"},{"issue":"14","key":"10141_CR110","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A et al (2020) KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med 382(14):1331\u20131342. https:\/\/doi.org\/10.1056\/NEJMoa1914347","journal-title":"N Engl J Med"},{"issue":"6","key":"10141_CR111","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.3390\/cancers14061501","volume":"14","author":"N Sharma","year":"2022","unstructured":"Sharma N, Reagan PM, Liesveld JL (2022) Cytopenia after CAR-T cell therapy\u2014a brief review of a complex problem. Cancers 14(6):1501. https:\/\/doi.org\/10.3390\/cancers14061501","journal-title":"Cancers"},{"key":"10141_CR112","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01969-y","author":"E Bachy","year":"2022","unstructured":"Bachy E, Le Gouill S, Di Blasi R et al (2022) A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med. https:\/\/doi.org\/10.1038\/s41591-022-01969-y","journal-title":"Nat Med"},{"issue":"27","key":"10141_CR113","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1200\/JCO.19.02103","volume":"38","author":"CA Jacobson","year":"2020","unstructured":"Jacobson CA, Hunter BD, Redd R et al (2020) Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity. J Clin Oncol 38(27):3095\u20133106. https:\/\/doi.org\/10.1200\/JCO.19.02103","journal-title":"J Clin Oncol"},{"key":"10141_CR114","unstructured":"Inc MG. CAR T-cells associated acute toxicity in B-cell non-Hodgkin... by Dr. Pierre Sesques. Accessed December 28, 2023. https:\/\/library.ehaweb.org\/eha\/2022\/eha2022-congress\/357074\/pierre.sesques.car.t-cells.associated.acute.toxicity.in.b-cell.non-hodgkin.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D2%2Asearch%3Dcar-t"},{"issue":"13","key":"10141_CR115","doi-asserted-by":"publisher","first-page":"3024","DOI":"10.1182\/bloodadvances.2020001972","volume":"4","author":"K Wudhikarn","year":"2020","unstructured":"Wudhikarn K, Pennisi M, Garcia-Recio M et al (2020) DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality. Blood Adv 4(13):3024\u20133033. https:\/\/doi.org\/10.1182\/bloodadvances.2020001972","journal-title":"Blood Adv"},{"issue":"10","key":"10141_CR116","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","volume":"22","author":"SJ Schuster","year":"2021","unstructured":"Schuster SJ, Tam CS, Borchmann P et al (2021) Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 22(10):1403\u20131415. https:\/\/doi.org\/10.1016\/S1470-2045(21)00375-2","journal-title":"Lancet Oncol"},{"issue":"24","key":"10141_CR117","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1182\/blood.2020010543","volume":"138","author":"K Rejeski","year":"2021","unstructured":"Rejeski K, Perez A, Sesques P et al (2021) CAR-HEMATOTOX: a model for CAR T-cell\u2013related hematologic toxicity in relapsed\/refractory large B-cell lymphoma. Blood 138(24):2499\u20132513. https:\/\/doi.org\/10.1182\/blood.2020010543","journal-title":"Blood"},{"issue":"38","key":"10141_CR118","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adg3919","volume":"9","author":"K Rejeski","year":"2023","unstructured":"Rejeski K, Perez A, Iacoboni G et al (2023) Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion. Sci Adv 9(38):eadg3919. https:\/\/doi.org\/10.1126\/sciadv.adg3919","journal-title":"Sci Adv"},{"issue":"11","key":"10141_CR119","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1002\/ajh.27056","volume":"98","author":"K Rejeski","year":"2023","unstructured":"Rejeski K, Wang Y, Albanyan O et al (2023) The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL. Am J Hematol 98(11):1699\u20131710. https:\/\/doi.org\/10.1002\/ajh.27056","journal-title":"Am J Hematol"},{"issue":"1","key":"10141_CR120","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01465-x","volume":"16","author":"K Rejeski","year":"2023","unstructured":"Rejeski K, Hansen DK, Bansal R et al (2023) The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed\/refractory multiple myeloma. J Hematol Oncol 16(1):88. https:\/\/doi.org\/10.1186\/s13045-023-01465-x","journal-title":"J Hematol Oncol"},{"issue":"10","key":"10141_CR121","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1182\/blood.2023020578","volume":"142","author":"K Rejeski","year":"2023","unstructured":"Rejeski K, Subklewe M, Aljurf M et al (2023) Immune effector cell\u2013associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations. Blood 142(10):865\u2013877. https:\/\/doi.org\/10.1182\/blood.2023020578","journal-title":"Blood"},{"issue":"12","key":"10141_CR122","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1038\/s41409-020-01006-x","volume":"55","author":"E Galli","year":"2020","unstructured":"Galli E, Allain V, Di Blasi R et al (2020) G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory\/relapsed B-cell lymphoma. Bone Marrow Transplant 55(12):2347\u20132349. https:\/\/doi.org\/10.1038\/s41409-020-01006-x","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10141_CR123","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/s41409-021-01526-0","volume":"57","author":"R Li\u00e9vin","year":"2022","unstructured":"Li\u00e9vin R, Di Blasi R, Morin F et al (2022) Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed\/refractory B-cell lymphoma. Bone Marrow Transplant 57(3):431\u2013439. https:\/\/doi.org\/10.1038\/s41409-021-01526-0","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10141_CR124","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.jcyt.2023.01.011","volume":"25","author":"S Ma","year":"2023","unstructured":"Ma S, Li H, Zhou D et al (2023) Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma. Cytotherapy 25(6):653\u2013658. https:\/\/doi.org\/10.1016\/j.jcyt.2023.01.011","journal-title":"Cytotherapy"},{"key":"10141_CR125","doi-asserted-by":"crossref","unstructured":"Rejeski K. Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations. CELL Ther. 2023;142(10).","DOI":"10.1182\/blood.2023020578"},{"issue":"15","key":"10141_CR126","doi-asserted-by":"publisher","first-page":"3776","DOI":"10.1182\/bloodadvances.2020002509","volume":"4","author":"T Jain","year":"2020","unstructured":"Jain T, Knezevic A, Pennisi M et al (2020) Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Adv 4(15):3776\u20133787. https:\/\/doi.org\/10.1182\/bloodadvances.2020002509","journal-title":"Blood Adv"},{"issue":"16","key":"10141_CR127","doi-asserted-by":"publisher","first-page":"4719","DOI":"10.1182\/bloodadvances.2022007776","volume":"6","author":"K Rejeski","year":"2022","unstructured":"Rejeski K, Burchert A, Iacoboni G et al (2022) Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy. Blood Adv 6(16):4719\u20134725. https:\/\/doi.org\/10.1182\/bloodadvances.2022007776","journal-title":"Blood Adv"},{"issue":"4","key":"10141_CR128","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1182\/bloodadvances.2022008042","volume":"7","author":"N Gagelmann","year":"2023","unstructured":"Gagelmann N, Wulf GG, Duell J et al (2023) Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy: a GLA\/DRST study. Blood Adv 7(4):555\u2013559. https:\/\/doi.org\/10.1182\/bloodadvances.2022008042","journal-title":"Blood Adv"},{"key":"10141_CR129","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2021.101422","volume":"71","author":"A Santoro","year":"2021","unstructured":"Santoro A, Bientinesi E, Monti D (2021) Immunosenescence and inflammaging in the aging process: age-related diseases or longevity? Ageing Res Rev 71:101422. https:\/\/doi.org\/10.1016\/j.arr.2021.101422","journal-title":"Ageing Res Rev"},{"issue":"26","key":"10141_CR130","doi-asserted-by":"publisher","first-page":"9194","DOI":"10.1073\/pnas.0503280102","volume":"102","author":"DJ Rossi","year":"2005","unstructured":"Rossi DJ, Bryder D, Zahn JM et al (2005) Cell intrinsic alterations underlie hematopoietic stem cell aging. Proc Natl Acad Sci U S A 102(26):9194\u20139199. https:\/\/doi.org\/10.1073\/pnas.0503280102","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"18","key":"10141_CR131","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1182\/blood-2016-01-688887","volume":"127","author":"C Silvestre-Roig","year":"2016","unstructured":"Silvestre-Roig C, Hidalgo A, Soehnlein O (2016) Neutrophil heterogeneity: implications for homeostasis and pathogenesis. Blood 127(18):2173\u20132181. https:\/\/doi.org\/10.1182\/blood-2016-01-688887","journal-title":"Blood"},{"issue":"7","key":"10141_CR132","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1097\/00003246-200107000-00002","volume":"29","author":"DC Angus","year":"2001","unstructured":"Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29(7):1303\u20131310. https:\/\/doi.org\/10.1097\/00003246-200107000-00002","journal-title":"Crit Care Med"},{"issue":"1","key":"10141_CR133","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-76781-0","volume":"10","author":"A Arcanjo","year":"2020","unstructured":"Arcanjo A, Logullo J, Menezes CCB et al (2020) The emerging role of neutrophil extracellular traps in severe acute respiratory syndrome coronavirus 2 (COVID-19). Sci Rep 10(1):19630. https:\/\/doi.org\/10.1038\/s41598-020-76781-0","journal-title":"Sci Rep"},{"issue":"6","key":"10141_CR134","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200652","volume":"217","author":"BJ Barnes","year":"2020","unstructured":"Barnes BJ, Adrover JM, Baxter-Stoltzfus A et al (2020) Targeting potential drivers of COVID-19: neutrophil extracellular traps. J Exp Med 217(6):e20200652. https:\/\/doi.org\/10.1084\/jem.20200652","journal-title":"J Exp Med"},{"issue":"6","key":"10141_CR135","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/JLB.1HI1120-779R","volume":"109","author":"Z He","year":"2021","unstructured":"He Z, Fahlberg MD, Takahashi N et al (2021) Declining neutrophil production despite increasing G-CSF levels is associated with chronic inflammation in elderly rhesus macaques. J Leukoc Biol 109(6):1033\u20131043. https:\/\/doi.org\/10.1002\/JLB.1HI1120-779R","journal-title":"J Leukoc Biol"},{"key":"10141_CR136","doi-asserted-by":"publisher","unstructured":"Bergenfelz C, Leandersson K. The generation and identity of human myeloid-derived suppressor cells. Front Oncol. 2020;10. Accessed September 6, 2022. https:\/\/www.frontiersin.org\/articles\/https:\/\/doi.org\/10.3389\/fonc.2020.00109","DOI":"10.3389\/fonc.2020.00109"},{"issue":"10","key":"10141_CR137","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1007\/s00018-019-03048-x","volume":"76","author":"A Salminen","year":"2019","unstructured":"Salminen A, Kaarniranta K, Kauppinen A (2019) Immunosenescence: the potential role of myeloid-derived suppressor cells (MDSC) in age-related immune deficiency. Cell Mol Life Sci 76(10):1901\u20131918. https:\/\/doi.org\/10.1007\/s00018-019-03048-x","journal-title":"Cell Mol Life Sci"},{"key":"10141_CR138","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.917972","volume":"13","author":"A Schroeter","year":"2022","unstructured":"Schroeter A, Roesel MJ, Matsunaga T, Xiao Y, Zhou H, Tullius SG (2022) Aging affects the role of myeloid-derived suppressor cells in alloimmunity. Front Immunol 13:917972. https:\/\/doi.org\/10.3389\/fimmu.2022.917972","journal-title":"Front Immunol"},{"issue":"1","key":"10141_CR139","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.clim.2012.01.011","volume":"143","author":"A Luyckx","year":"2012","unstructured":"Luyckx A, Schouppe E, Rutgeerts O et al (2012) G-CSF stem cell mobilization in human donors induces polymorphonuclear and mononuclear myeloid-derived suppressor cells. Clin Immunol 143(1):83\u201387. https:\/\/doi.org\/10.1016\/j.clim.2012.01.011","journal-title":"Clin Immunol"},{"issue":"4","key":"10141_CR140","doi-asserted-by":"publisher","first-page":"398","DOI":"10.2307\/2406060","volume":"11","author":"GC Williams","year":"1957","unstructured":"Williams GC (1957) Pleiotropy, natural selection, and the evolution of senescence. Evolution 11(4):398. https:\/\/doi.org\/10.2307\/2406060","journal-title":"Evolution"},{"issue":"26","key":"10141_CR141","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","volume":"371","author":"G Genovese","year":"2014","unstructured":"Genovese G, K\u00e4hler AK, Handsaker RE et al (2014) Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 371(26):2477\u20132487. https:\/\/doi.org\/10.1056\/NEJMoa1409405","journal-title":"N Engl J Med"},{"issue":"6","key":"10141_CR142","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1182\/blood-2017-02-769869","volume":"130","author":"F Zink","year":"2017","unstructured":"Zink F, Stacey SN, Norddahl GL et al (2017) Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly. Blood 130(6):742\u2013752. https:\/\/doi.org\/10.1182\/blood-2017-02-769869","journal-title":"Blood"},{"issue":"1","key":"10141_CR143","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ygyno.2022.01.024","volume":"165","author":"F Trillsch","year":"2022","unstructured":"Trillsch F, Mahner S, Ataseven B et al (2022) Efficacy and safety of olaparib according to age in BRCA1\/2-mutated patients with recurrent platinum-sensitive ovarian cancer: analysis of the phase III SOLO2\/ENGOT-Ov21 study. Gynecol Oncol 165(1):40\u201348. https:\/\/doi.org\/10.1016\/j.ygyno.2022.01.024","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10141_CR144","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s40266-022-01005-1","volume":"40","author":"L Balducci","year":"2023","unstructured":"Balducci L, Falandry C, List A (2023) A proactive approach to prevent hematopoietic exhaustion during cancer chemotherapy in older patients: temporary cell-cycle arrest. Drugs Aging 40(3):263\u2013272. https:\/\/doi.org\/10.1007\/s40266-022-01005-1","journal-title":"Drugs Aging"},{"key":"10141_CR145","doi-asserted-by":"publisher","unstructured":"Balducci L, Falandry C, Silvio Monfardini. Senotherapy, cancer, and aging. J Geriatr Oncol. Published online November 2023:101671. https:\/\/doi.org\/10.1016\/j.jgo.2023.101671","DOI":"10.1016\/j.jgo.2023.101671"},{"key":"10141_CR146","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102427","volume":"109","author":"DW Blayney","year":"2022","unstructured":"Blayney DW, Schwartzberg L (2022) Chemotherapy-induced neutropenia and emerging agents for prevention and treatment: a review. Cancer Treat Rev 109:102427. https:\/\/doi.org\/10.1016\/j.ctrv.2022.102427","journal-title":"Cancer Treat Rev"},{"key":"10141_CR147","doi-asserted-by":"publisher","unstructured":"Daniel D, Kuchava V, Bondarenko I, et al. Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: a multicentre, randomised, double-blind, placebo-controlled Phase II trial. Int J Cancer. Published online December 21, 2020. https:\/\/doi.org\/10.1002\/ijc.33453","DOI":"10.1002\/ijc.33453"},{"key":"10141_CR148","doi-asserted-by":"publisher","first-page":"6207","DOI":"10.2147\/CMAR.S313045","volume":"13","author":"M Hussein","year":"2021","unstructured":"Hussein M, Maglakelidze M, Richards DA et al (2021) Myeloprotective effects of trilaciclib among patients with small cell lung cancer at increased risk of chemotherapy-induced myelosuppression: pooled results from three phase 2, randomized, double-blind, placebo-controlled studies. Cancer Manag Res 13:6207\u20136218. https:\/\/doi.org\/10.2147\/CMAR.S313045","journal-title":"Cancer Manag Res"},{"issue":"1","key":"10141_CR149","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/febs.13555","volume":"283","author":"Y Wang","year":"2016","unstructured":"Wang Y, Zhang H, Gigant B et al (2016) Structures of a diverse set of colchicine binding site inhibitors in complex with tubulin provide a rationale for drug discovery. FEBS J 283(1):102\u2013111. https:\/\/doi.org\/10.1111\/febs.13555","journal-title":"FEBS J"},{"issue":"2","key":"10141_CR150","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00280-019-03998-w","volume":"85","author":"JR Tonra","year":"2020","unstructured":"Tonra JR, Lloyd GK, Mohanlal R, Huang L (2020) Plinabulin ameliorates neutropenia induced by multiple chemotherapies through a mechanism distinct from G-CSF therapies. Cancer Chemother Pharmacol 85(2):461\u2013468. https:\/\/doi.org\/10.1007\/s00280-019-03998-w","journal-title":"Cancer Chemother Pharmacol"},{"issue":"14","key":"10141_CR151","doi-asserted-by":"publisher","first-page":"9401","DOI":"10.1021\/acs.jmedchem.3c00623","volume":"66","author":"V Guerlavais","year":"2023","unstructured":"Guerlavais V, Sawyer TK, Carvajal L et al (2023) Discovery of sulanemadlin (ALRN-6924), the first cell-permeating, stabilized \u03b1-helical peptide in clinical development. J Med Chem 66(14):9401\u20139417. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c00623","journal-title":"J Med Chem"},{"key":"10141_CR152","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.freeradbiomed.2021.05.003","volume":"171","author":"SM Lagoumtzi","year":"2021","unstructured":"Lagoumtzi SM, Chondrogianni N (2021) Senolytics and senomorphics: natural and synthetic therapeutics in the treatment of aging and chronic diseases. Free Radic Biol Med 171:169\u2013190. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2021.05.003","journal-title":"Free Radic Biol Med"},{"issue":"5","key":"10141_CR153","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1111\/febs.16350","volume":"290","author":"L Zhang","year":"2023","unstructured":"Zhang L, Pitcher LE, Prahalad V, Niedernhofer LJ, Robbins PD (2023) Targeting cellular senescence with senotherapeutics: senolytics and senomorphics. FEBS J 290(5):1362\u20131383. https:\/\/doi.org\/10.1111\/febs.16350","journal-title":"FEBS J"},{"issue":"5","key":"10141_CR154","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1152\/physiol.00003.2023","volume":"38","author":"S Aratani","year":"2023","unstructured":"Aratani S, Nakanishi M (2023) Recent advances in senolysis for age-related diseases. Physiology 38(5):205\u2013216. https:\/\/doi.org\/10.1152\/physiol.00003.2023","journal-title":"Physiology"},{"issue":"9","key":"10141_CR155","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1096\/fba.2019-00041","volume":"1","author":"M Feng","year":"2019","unstructured":"Feng M, Kim J, Field K, Reid C, Chatzistamou I, Shim M (2019) Aspirin ameliorates the long-term adverse effects of doxorubicin through suppression of cellular senescence. FASEB Bioadv 1(9):579\u2013590. https:\/\/doi.org\/10.1096\/fba.2019-00041","journal-title":"FASEB Bioadv"},{"issue":"2","key":"10141_CR156","doi-asserted-by":"publisher","first-page":"480","DOI":"10.14336\/AD.2020.0702","volume":"12","author":"D Hu","year":"2021","unstructured":"Hu D, Xie F, Xiao Y et al (2021) Metformin: a potential candidate for targeting aging mechanisms. Aging Dis 12(2):480\u2013493. https:\/\/doi.org\/10.14336\/AD.2020.0702","journal-title":"Aging Dis"},{"issue":"6","key":"10141_CR157","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10061295","volume":"10","author":"A Awadalla","year":"2022","unstructured":"Awadalla A, Hussein AM, El-Far YM et al (2022) Rapamycin improves adipose-derived mesenchymal stem cells (ADMSCs) renoprotective effect against cisplatin-induced acute nephrotoxicity in rats by inhibiting the mTOR\/AKT signaling pathway. Biomedicines 10(6):1295. https:\/\/doi.org\/10.3390\/biomedicines10061295","journal-title":"Biomedicines"},{"issue":"5","key":"10141_CR158","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14051001","volume":"14","author":"AM Shawky","year":"2022","unstructured":"Shawky AM, Almalki FA, Abdalla AN, Abdelazeem AH, Gouda AM (2022) A comprehensive overview of globally approved JAK inhibitors. Pharmaceutics 14(5):1001. https:\/\/doi.org\/10.3390\/pharmaceutics14051001","journal-title":"Pharmaceutics"},{"issue":"1\u20132","key":"10141_CR159","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cell.2016.12.012","volume":"168","author":"Q Zhang","year":"2017","unstructured":"Zhang Q, Lenardo MJ, Baltimore D (2017) 30 years of NF-\u03baB: a blossoming of relevance to human pathobiology. Cell 168(1\u20132):37\u201357. https:\/\/doi.org\/10.1016\/j.cell.2016.12.012","journal-title":"Cell"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-10141-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-025-10141-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-10141-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T08:59:38Z","timestamp":1769677178000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-025-10141-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":159,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10141"],"URL":"https:\/\/doi.org\/10.1007\/s00520-025-10141-4","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"23 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The affiliations have been corrected.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CF, PS, WJ, GA, VT, LB. Received honoraria as members of the Scientific Committee of the NEW Group (Neutropenic Event Working Group). KM is a Chugai Pharma France employee. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"1161"}}